scholarly journals The Adhesion Molecule Esam1 Is a Novel Hematopoietic Stem Cell Marker

Stem Cells ◽  
2009 ◽  
Vol 27 (3) ◽  
pp. 653-661 ◽  
Author(s):  
A. G. Lisa Ooi ◽  
Holger Karsunky ◽  
Ravindra Majeti ◽  
Stefan Butz ◽  
Dietmar Vestweber ◽  
...  
2015 ◽  
Vol 43 (9) ◽  
pp. S69
Author(s):  
Tomohiko Ishibashi ◽  
Takafumi Yokota ◽  
Hirokazu Tanaka ◽  
Michiko Ichii ◽  
Takao Sudo ◽  
...  

2004 ◽  
Vol 319 (1) ◽  
pp. 15-26 ◽  
Author(s):  
Mareike Florek ◽  
Michael Haase ◽  
Anne-Marie Marzesco ◽  
Daniel Freund ◽  
Gerhard Ehninger ◽  
...  

Hepatology ◽  
1998 ◽  
Vol 27 (2) ◽  
pp. 433-445 ◽  
Author(s):  
Bryon E. Petersen ◽  
Julie P. Goff ◽  
Joel S. Greenberger ◽  
George K. Michalopoulos

2016 ◽  
Vol 44 (4) ◽  
pp. 269-281.e1 ◽  
Author(s):  
Tomohiko Ishibashi ◽  
Takafumi Yokota ◽  
Hirokazu Tanaka ◽  
Michiko Ichii ◽  
Takao Sudo ◽  
...  

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 564-564
Author(s):  
Ingrid G Winkler ◽  
Valerie Barbier ◽  
Bianca Nowlan ◽  
Theodore Smith ◽  
John T Patton ◽  
...  

Abstract Abstract 564 The behaviour of a hematopoietic stem cell (HSC) is regulated by its immediate micro-environment or niche. We have identified a novel function for the adhesion molecule E-selectin which is constitutively expressed on bone marrow (BM) vasculature. Using mice knocked-out for E- (E-/-) or P-selectin (P-/-) genes, we investigated whether selectin absence alters HSC behaviour in vivo. We found HSC cycling in the absence of E-selectin to be significantly delayed 2.5-fold in BrdU incorporation assays compared to either P-/- or WT (mice were administered BrdU for 3d then BrdU incorporation in BM Lineage-KIT+Sca1+(LKS+)CD34- or LKS+CD48-CD150+cells measured). To confirm these findings, LKS+ cells were stained with rhodamine123, a vital dye retained by metabolically active cells but not quiescent HSC. More LKS+ cells from E-/- mice were rhodamine dull (34±2%) than WT (23±1%; p=0.037) confirming that a greater proportion of HSC from E-/- mice are quiescent. We then determined whether administration of E-selectin antagonists alone could similarly delay HSC turnover. Mice were administered the glycomimetic E-selectin antagonist GMI-1070, for set periods of time before harvest. We found HSC turnover to be significantly delayed following GMI-1070 administration (1.4 fold less BrdU incorporation, p=0.011) with a concomitant 1.4-fold increase in the number of Rho123 dull LSK+ quiescent HSC per femur (p=0.020). Non-cycling, quiescent HSC are known to be more resistant to chemotherapy and irradiation. Indeed 7 days following 5-FU administration, we found that E-/- mice had faster BM HSC recovery / less HSC damage compared to WT mice, both by phenotype analysis and in a competitive long-term reconstituting assay. Following 5-FU administration the number of reconstituting units/femur in WT mice decreased 5.1-fold but only decreased 2.3-fold in similarly treated E-/- mice. Interestingly, when mice were pre-treated with GMI-1070 before 5-FU, there was significantly enhanced blood neutrophil recovery compared to mice administered 5-FU alone (blood neutrophils were 710±205 ×103/mL with GMI-1070, compared to 234±141 ×103/mL without, at day 9 post-5-FU, p=0.0001). Similarly when mice were severely irradiated and test bleeds performed weekly, a more rapid haematopoietic recovery was observed in E-/- compared to WT mice. In summary, we have identified a novel function for the adhesion molecule E-selectin. HSC turnover is dramatically reduced in E-/- mice an effect that can be replicated by transient administration of E-selectin antagonist mimetics. Furthermore blood leukocyte and HSC numbers recover faster following cytotoxic or irradiation injury in the absence or blockage of E-selectin-mediated cell adhesion. Thus E-selectin may well be a crucial component of the proliferative HSC niche regulating HSC turnover. Blockage of E-selectin adhesive interaction by GMI-1070, a novel E-selectin antagonist that has completed phase I clinical trails, may represent a promising treatment for the protection of HSC during chemotherapy. Disclosures: Winkler: Glycomimetics Inc: Research Funding. Smith:GlycoMimetics, Inc: Employment. Patton:GlycoMimetics, Inc: Employment. Magnani:GlycoMimetics, Inc.: Employment. Levesque:Glycomimetics Inc.: Research Funding.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 4303-4303
Author(s):  
Laura R. Goldberg ◽  
Mark S Dooner ◽  
Yanhui Deng ◽  
Elaine Papa ◽  
Mandy Pereira ◽  
...  

Abstract The study of highly purified hematopoietic stem cells (HSCs) has dominated the field of hematopoietic stem cell biology. It is widely believed that the true stem cell population lies within the Lineage negative (Lin-) population, further sub-fractionated using positive and negative selection for surface markers such as c-Kit, Sca-1, CD150, CD41, CD48, and CD34. It is research on these highly purified subsets of HSCs that forms the foundation for almost all our knowledge of HSCs, and has led to the dogma that marrow stem cells are quiescent with a stable phenotype and therefore can be purified to near homogeneity. In contrast, we have shown that a large percentage of long-term multi-lineage marrow repopulating cells in whole bone marrow (WBM) are actively cycling, that these cycling stem cells are lost during conventional HSC isolation, and that they can be found, in part, within the discarded Lineage positive (Lin+) population. Here we present data further characterizing the stem cell potential in the Lin+ fraction. We incubated WBM from B6.SJL mice with fluorescently tagged antibodies directed against TER119, B220, or T-cell markers (CD3, CD4, CD8), isolated the distinct Lin+ subsets by FACS, and then competitively engrafted each Lin+ subset into lethally irradiated C57BL/6 host mice. Donor chimerism and lineage specificity of donor cells in peripheral blood were analyzed by flow cytometry at 3 months. Although classically considered devoid of stem cell activity, we found that, when competed against equal numbers of C57BL/6 WBM, the TER119+ and B220+ B6.SJL donor cells contributed to 33% and 13% of the peripheral blood chimerism, respectively. In both cases, the engraftment was multi-lineage. When 70,000 T cell marker+ donor cells were competed with 300,000 C57BL/6 WBM, the donor cells contributed up to 1.6% of the peripheral blood multi-lineage chimerism. Given the size of the Lin+ fraction in WBM, such chimerism indicates a significant stem cell potential within this typically discarded population. Further time-points, secondary transplants and limited dilution studies are in progress to further define the prevalence and potency of this stem cell population. We have been testing mechanisms governing the loss of this stem cell population during HSC purification. First, we have previously shown that bulk Lin+ engraftment potential is due to cycling stem cells. We hypothesize that fluctuations in surface epitope expression with cell cycle transit render this population difficult to isolate with antibody-mediated strategies that rely on stable epitope expression. To begin testing this, we tracked the fluctuation of stem cell markers on Lin- cells in vitro. We isolated Lin- cells that were also negative for the stem cell markers c-Kit and Sca-1, placed them in liquid culture and, 18 hours later, re-assessed for stem cell marker expression by flow cytometry. We found that, although initially stem cell marker negative, up to 6%, 14%, and 2% of the Lin-/stem cell marker negative cells became positive for c-Kit alone, Sca-1 alone, or both c-Kit and Sca-1 expression, respectively. We are currently testing this population for a correlation between gain of c-Kit- and Sca-1 expression and stem cell function. Second, it is possible that there is a distinct subset of HSCs that are positive for both Lin+ markers and stem cell markers with stable stem cell capacity and that these distinct stem cells are thrown out in the process of lineage depletion. To begin testing this hypothesis, we have simultaneously stained WBM with antibodies directed against the Lin+ markers and conventional stem cell markers. Our preliminary data indicate that each Lin+ fraction tested to date has a subpopulation that is also positive for c-Kit and Sca-1. For example, 21% of CD3+ cells, 6.2% of CD4+ cells, 2.26% of CD8+ cells, 0.5% of B220+, and 0.45% of TER119+ cells express both c-Kit and Sca-1. We suspect these two populations have distinct functional phenotypes and experiments characterizing the molecular phenotype and engraftment capacity of these subpopulations are ongoing. In sum, our data indicate that stem cell purification skews isolation towards a small population of quiescent stem cells, underrepresenting a potentially large pool of actively cycling HSCs that are found within the Lin+ fraction. These data underscore the need to re-evaluate the total hematopoietic stem cell potential in marrow on a population level. Disclosures No relevant conflicts of interest to declare.


Stem Cells ◽  
2007 ◽  
Vol 25 (2) ◽  
pp. 279-288 ◽  
Author(s):  
Jennifer B. Gilner ◽  
William G. Walton ◽  
Kimberly Gush ◽  
Suzanne L. Kirby

1997 ◽  
Vol 138 (6) ◽  
pp. 1395-1407 ◽  
Author(s):  
Kelly M. McNagny ◽  
Inger Pettersson ◽  
Fabio Rossi ◽  
Ingo Flamme ◽  
Andrej Shevchenko ◽  
...  

MEP21 is an avian antigen specifically expressed on the surface of Myb-Ets–transformed multipotent hematopoietic precursors (MEPs) and of normal thrombocytes. Using nanoelectrospray tandem mass spectrometry, we have sequenced and subsequently cloned the MEP21 cDNA and named the gene thrombomucin as it encodes a 571–amino acid protein with an extracellular domain typical of the mucin family of proteoglycans. Thrombomucin is distantly related to CD34, the best characterized and most used human hematopoietic stem cell marker. It is also highly homologous in its transmembrane/intracellular domain to podocalyxinlike protein–1, a rabbit cell surface glycoprotein of kidney podocytes. Single cell analysis of yolk sac cells from 3-d-old chick embryos revealed that thrombomucin is expressed on the surface of both lineage-restricted and multipotent progenitors. In the bone marrow, thrombomucin is also expressed on mono- and multipotent progenitors, showing an overlapping but distinct expression pattern from that of the receptor-type stem cell marker c-kit. These observations strengthen the notion that the Myb-Ets oncoprotein can induce the proliferation of thrombomucin-positive hematopoietic progenitors that have retained the capacity to differentiate along multiple lineages. They also suggest that thrombomucin and CD34 form a family of stem cell–specific proteins with possibly overlapping functions in early hematopoietic progenitors.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 126-126
Author(s):  
Milton A. English ◽  
Lin Lei ◽  
Trevor Blake ◽  
Raman Sood ◽  
Paul P. Liu

Abstract Hematopoiesis is a tightly regulated process that requires the coordinated efforts of many tissue-specific transcription factors. Lateral mesoderm tissue undergoes a series of restricted proliferation and differentiation that result in the production of the hematopoietic stem cells. These cells then differentiate to populate the different cell lineages. While some factors essential for this process have been defined, many remain unknown. Zebrafish offer a powerful model system in which it is possible to conduct forward phenotype-driven screening. We have undertaken a chemical mutagenesis screen using N-nitroso-N-ethylurea (ENU) in the zebrafish to uncover mutants in myelopoiesis and early hematopoiesis. Adult male fish were exposed to ENU in a protocol designed to mutagenize spermatagonia with a mutation frequency of approximately 1:1000. Mutagenized males were crossed to wild-type females to generate F1 females. Haploid embryos from F1 females were screened at 27 hours of development by RNA in situ hybridization using the myeloid-specific marker, leukocyte-specific plastin (l-plastin), and the stem cell marker, core binding factor b (cbfb). One mutant line identified from this screen, mummy, showed reduced cbfb expression and lack of l-plastin expression. Additional in situ staining has confirmed that mummy has a myeloid defect as other myeloid markers such as Lys.C, Mpo, and C/ebp1 were also significantly reduced. Mummy mutant also have a degreased expression of gata1 and bE1 globin (RBC markers) as well as the stem cell marker scl. These results suggested that the defect in mummy is at or up-stream of the HSC level. The mummy mutant embryos also suffer from widespread cell death and die around 36 hours post fertilization. Genetic mapping and positional cloning has identified the mutated gene as the zebrafish homolog of DHX8, which encodes an RNA helicase. The yeast homolog of dhx8, prp22, functions during mRNA splicing and RNA processing. Morpholino injection into wild-type embryos has confirmed that reduced expression of dhx8 can produce a similar phenotype. The wild-type zebrafish dhx8 cDNA but not the mutated dhx8 cDNA identified in mummy was able to partially rescue the mummy phenotype. Preliminary data from RT-PCR and microarray analysis suggest that mummy mutants have defects in the production of spliced transcripts of some genes but not others. Genes with decreased spliced transcripts in the mummy mutant include scl, cbfb, and gata1, which may explain the hematpoietic defects observed. Our results demonstrate that mutations in an RNA helicase involved in splicing could result in specific blockage of hematopoiesis.


Sign in / Sign up

Export Citation Format

Share Document